Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates

DBCAT004539Pharmacologic class

This category has been created to cover the interactions between monoamine oxidase A (MAO-A) substrates and MAO-A inhibitors. This "inhibitors" category is separate from the originally created, "Monoamine Oxidase A Inhibitors" category, which could not... A DrugBank category of 59 drugs. 34 of them are approved.

Drugs: 4-Methoxyamphetamine
7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE
Amitriptyline
AS-602868
Befloxatone
Bilberry
Brofaromine
Cannabichromene
Capsaicin
Clorgiline
Contezolid
Decyl(dimethyl)phosphine oxide
Ephedra sinica root
Esuprone
Etryptamine
Fabomotizole
Flavin adenine dinucleotide
Furazolidone
Ginkgo biloba
Harmine
Indantadol
Indopan
Iproniazid
Isocarboxazid
J147
and 34 more with a free account

What you can answer from here — as of April 11, 2019

59DrugsEach linked to its full drug card

244Drug targetsEvery drug–target pair in the class, with bond type

10,419Marketed productsAcross the regions we cover, with dosage forms and routes

16Routes of administrationHow the drugs in this class are given

Which targets do Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account